Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Johnson

Trauma Surgery Panama City, FL Medical Doctor

NPI 1992191746 CMS profile 7792419

801 E 6Th St Ste 606, Panama City, FL 32401

Open in the dashboard

General payments

$32,638

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Johnson of Panama City, FL is reported in the CMS Open Payments database as having received $32,638 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Trauma Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $253 5
2024 General $2,856 27
2023 General $10,863 18
2022 General $17,828 21
2021 General $601 9
2020 General $218 3
2019 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Johnson
  • Trauma Surgery median
  • Middle half of Trauma Surgery
  • National median

In program year 2025, general payments to Christopher Johnson were reported at $253. Among 762 Trauma Surgery profiles paid that year, the median was $280 and the middle half received between $87 and $1,585.

Show as a table
Year Christopher Johnson Trauma Surgery median Middle half National median
2019 $19 $153 $56–$644 $163
2020 $218 $123 $39–$342 $114
2021 $601 $142 $45–$556 $132
2022 $17,828 $172 $59–$732 $149
2023 $10,863 $213 $83–$1,200 $160
2024 $2,856 $237 $86–$1,280 $164
2025 $253 $280 $87–$1,585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $28,419 40 payments
  2. W. L. Gore & Associates, Inc. $1,594 15 payments
  3. Enterra Medical, Inc. $1,402 8 payments
  4. Davol Inc. $268 4 payments
  5. Medtronic, Inc. $157 2 payments
  6. Ethicon US, LLC $154 2 payments
  7. TELA Bio, Inc. $146 1 payment
  8. Endogastric Solutions, Inc $130 1 payment
  9. Next Science LLC $83 1 payment
  10. Baxter Healthcare $79 1 payment
  11. Other $205 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $25,000 7 payments
  2. Food and Beverage $4,629 65 payments
  3. Travel and Lodging $2,510 11 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $26,919 38 payments
  2. GORE SYNECOR Biomaterial $1,390 12 payments
  3. DAVINCI XI $1,000 1 payment
  4. DA VINCI SP $500 1 payment
  5. PHASIX $196 2 payments
  6. GORE ENFORM Preperitoneal Biomaterial $158 2 payments
  7. OviTex 2S $146 1 payment
  8. EndoFlip $134 1 payment
  9. EsophyX $130 1 payment
  10. HARMONIC Product Family $123 1 payment
  11. Other $464 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

144

Median for General Surgery: 59

Drug cost

$1,689

Median for General Surgery: $393

Branded share of claims

45.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 18 $1,075
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 48 $289
Ondansetron Hcl Generic 40 $187
Neomycin Sulfate Generic 19 $110
Metronidazole Generic 19 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$100,854

Medicare's payments for the services billed

Medicare patients

233

Average age 72

Services billed

542

132 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 45%
Chronic kidney disease 41%
Diabetes 36%
Heart failure 32%
Depression 31%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Trauma Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record